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Currently, several viruses are being assessed for their use as antitumor agents. For this purpose, targeting of viruses to epitopes on tumor cells is often essential to achieve a tumor-specific infection. In this study, we determined whether a recombinant non-human coronavirus, i.e. a mouse hepatitis virus with feline tropism (fMHV), could be targeted to an epitope over-expressed on human tumor cells. The main advantages of coronaviruses over the currently used viral vectors when aiming at viral tumor therapy are that they have a short replication cycle and, consequently, lead to rapid killing of their target cells. Here, we constructed a recombinant bispecific antibody, consisting of a neutralizing anti-feline spike protein single chain variable fragment (scFv) antibody (23F) fused to a scFv (425) directed against the epidermal growth factor receptor (EGFR). The resulting bispecific scFv protein mediated fMHV infection on a panel of EGFR-expressing human cancer cell lines, including HeLa, OVCAR-3, HCT-81, Widr, Caco-2, and HepG2 cells, as demonstrated by immunostaining with a virus-specific MAb. In contrast, inoculation of these cell lines with fMHV in the absence of bispecific scFv protein did not result in any detectable infection. In addition, a derivative of the murine cell line NIH-3T3 stably expressing the EGFR could be infected with fMHV, whereas parental NIH-3T3 cells could not, confirming the specificity of the infection via EGFR. This was further corroborated by the finding that infection of human tumor cell lines using the bispecific fusion protein could be blocked with MAb 23F8.1 or Mab 425, the anti-spike and anti-EGFR antibodies respectively, from which the two scFv were derived. In conclusion, fMHV can be selectively targeted to human tumor cells by using a bispecific targeting device. This result provides a rationale for further investigations on the use of coronaviruses as anti-tumor agents.
